It's no secret that despite a spike in FDA approvals, the biopharma industry has been going through a long and devastating innovation drought. The low rate of new drug approvals threatens the very existence of the pharma business as we know it. Only leaders who can buck that trend--and create one of their own--will survive.It's against that backdrop that FierceBiotech and FiercePharma present a look at the newsmakers who promise to blaze a trail for others to follow. And it's not just a listing of CEOs. Our report includes an R&D revolutionary, a woman who built her own sizable venture in India, research executives busily mapping new R&D strategies, a developer-turned-university chancellor who has her own views on the brave new world to come and where academics fit into it, along with several others.
Click en cada nombre para ver perfil completo.
I wrote part of this report, with Suzanne Elvidge, Mark Hollmer, Ryan McBride and Tracy Staton shouldering the bulk of the work. I'd like some feedback here from readers for next year, when we'll be back with another annual report on influentials. - John Carroll, editor-in-chief
La "Big Pharma" está presente:
Amgen (Bradway), Merck (Frazier), Abbott (Gonzalez), Takeda (Hasegawa), Novartis (Jimenez), Teva (Levin), Pfizer (Read), Biogen (Scangos), Roche (Schwan), Glaxo (Slaoui), Novo (Sorensen), Sanofi (Viehbacher), Glaxo (Witty).
Entradas
